YaoYi Life Sciences Completes Angel Financing Round Led by QinZhi PetLe Pharma Fund

VCBeat learned at the earliest opportunity,Dongguan Yaoyi Life Technology Co., Ltd. (hereinafter referred to as "Yaoyi Life")Announced the successful completion of its angel round of financing, which was led byDiligenceZhiChongLe Medical FundLead investor. The funds from this round will be primarily used to advance clinical trials of the company’s core pipeline, further accelerating the development of its platform-based technologies and pipeline expansion.

Yaoyi Life, established in 2023, leveragesMicro/Nano Materials and Polymer Regulated Assembly Technology Platform, focusing onVeterinary health products, including vaccine adjuvants, nanozyme formulations for gut microbiota modulation, antibacterial and anti-inflammatory hydrogels, hemostatic tissue adhesives, and interventional embolization materials...development. The company is dedicated to addressing key pain points in animal vaccine adjuvants and drug delivery platform technologies, driving innovative development in the animal health sector. Leveraging its core platform technologies, Dongguan Yaoyi Life Technology Co., Ltd. effectively enhances the efficacy of animal health pharmaceuticals and broadens their scope of application, significantly improving the convenience and therapeutic outcomes for treating sick pets.

As a breakthrough advancement, auxiliary drug-loading platform technology holds promise for addressing long-standing challenges in veterinary medicine, including insufficient efficacy, prolonged R&D cycles, poor cross-species adaptability, and safety concerns.For example, in the field of animal vaccines, optimized adjuvants can not only enhance immunogenicity and immune responses but also address the issue of inconsistent vaccine efficacy. To this end, the core team at Yaoyi Life has dedicated years to research and development, achieving significant breakthroughs in synthesis processes, formulation control, drug stability, and release control.^[1,2]. By optimizing drug release profiles and biocompatibility, these platform technologies not only significantly enhance immunogenic performance but also substantially prolong therapeutic durability and improve dosing convenience, thereby providing robust technical support for the innovation of treatment regimens across multiple industries.

The company’s inaugural product is a novel biosafe aqueous adjuvant with controlled antigen release, developed for veterinary vaccines. It serves both as a physical antigen carrier and as a sustained-release platform, enabling single-dose administration to provide protection lasting several months and thereby reducing the burden of repeated dosing in animals.Exquisite design ensures long-lasting immunostimulatory effects, significantly enhancing therapeutic efficacy and providing more innovative, efficient, and accessible treatment options for veterinary medicine.

Furthermore, hydrogel platform technology also demonstrates broad prospects in the field of medical aesthetics.Yaoyi Life is laying out its hydrogel product pipeline for minimally invasive medical aesthetic repair.By regulating the release of active factors, it achieves deep nourishment and tissue regeneration, accelerates wound healing, and improves skin quality, providing a safe, long-lasting, and highly effective repair solution for the medical aesthetics market.

For this round of financing,Dr. Zhang Lei, Founder of Yaoyi Life“We sincerely appreciate the trust and support of the investors in this funding round. We will accelerate the clinical development of our products to provide safer and more effective potentiation solutions for the veterinary pharmaceutical sector, addressing the urgent needs of animal healthcare. Leveraging the Yaoyi platform, we will explore greater possibilities in platform-based drug delivery technologies for veterinary therapeutics, expedite the R&D and commercialization of innovative products, and strive to become a leader in the development of platform technologies for animal health pharmaceuticals.”

Qinzhi Chongle Fund“QinZhi ChongLe Biopharmaceutical Fund is honored to collaborate with all parties in supporting Yaoyi Life’s first round of market-oriented financing. The field of animal health is complex and nuanced; safeguarding animal health is a shared responsibility for all humanity, and there remain many unmet clinical needs. The core team at Yaoyi Life boasts profound expertise and exceptional execution capabilities in platform technologies for animal healthcare pharmaceuticals. We firmly believe that, underpinned by this platform technology, Yaoyi Life will enjoy broader development prospects. We look forward to the early market launch of Yaoyi Life’s innovative products, providing more efficient solutions for clinical practice.”

Qinzhi Chongle Fund was established in October 2022 as a key strategic initiative by Qinzhi Capital in the pet healthcare sector. It was jointly founded with Nova Li Hua, Shilong Industrial Investment, and multiple industrial capital firms from Dongguan City. As part of Qinzhi Capital’s new direction in the biopharmaceutical field—integrating “space, industry, and layout”—the fund is dedicated to deepening its engagement across the pet healthcare value chain and building a comprehensive platform to support innovative enterprises in this space. The fund aims to address core challenges in pet pharmaceutical R&D, thereby fostering technological innovation and industry development. Since its inception, Qinzhi Chongle has successfully incubated and invested in several industry-leading companies, including Hertz Life, a leading enterprise in pet vaccines, and Nanxing Digital, a domestic digital animal health company. Through precise strategic positioning, Qinzhi Chongle continues to drive technological breakthroughs and industrial upgrading in the pet healthcare sector, striving to lead the future development of the industry.

References:

[1] Tian T, Wang J, Yin F, et al. Activation of Cascade‐Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT [J]. Advanced Healthcare Materials, 2022, 11(1): 2102080.

[2] Tian T, Wang J, Wang W, et al. Colloidal Hydrogel for Sensitizing Microwave Ablation‐Induced in Situ Tumor Vaccination and Modulating Innate and Adaptive Immunotherapy [J]. Advanced Functional Materials, 2024: 2403118.